Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 601–700 of 1,041
Abd-Ellatef, G. E. F., Gazzano, E., Chirio, D., Hamed, A. R., Belisario, D. C., Zuddas, C., Peira, E., Rolando, B., Kopecka, J., Marie, M. A. S., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020096 · Cited by 136
“The main ABC transporters clinically associated with the development of MDR are P-glycoprotein (Pgp/ABCB1), MDR Related Proteins (MRPs/ABCCs), and Breast Cancer Resistance Protein (BCRP/ABCG2) [4,5].”
BackgroundDornetshuber, R., Heffeter, P., Kamyar, M.-R., Peterbauer, T., Berger, W., & Lemmens‐Gruber, R. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600259t · Cited by 142
Lepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D., & Sparreboom, A. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.2.115 · Cited by 142
The ABC transporter gene family of Daphnia pulex
Sturm, A., Cunningham, P., & Dean, M. C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-170 · Cited by 143
“Drug efflux transporters are found in ABC subfamilies B, C and G [18], and in normal tissues often show an apical expression in epithelia involved in excretion or forming boundaries of the body, reflecting their role in the biochemical defence against toxicants [19].”
BackgroundPichler, A., Prior, J. L., & Piwnica-Worms, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304326101 · Cited by 129
Chearwae, W., Shukla, S., Limtrakul, P., & Ambudkar, S. V. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0087 · Cited by 130
“Development of multidrug resistance (MDR) is a problem in cancer chemotherapy that limits the effectiveness of anticancer drugs (1, 2).”
BackgroundLiao, C.-H., Pan, S., Guh, J., Chang, Y.-L., Pai, H., Lin, C., & Teng, C. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi041 · Cited by 139
Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells
Guo, X., Ma, N., Wang, J., Song, J., Bu, X., Cheng, Y., Sun, K., Xiong, H., Jiang, G., Zhang, B., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-375 · Cited by 130
“Many different mechanisms have been suggested to explain the development of a MDR phenotype in cancer cells, one of the extensively studied form of these mechanisms is overexpression of several energy dependent drug efflux pumps that belong to the ATP-binding cassette family of transporters, such as the P-glycoprotein…”
BackgroundCan nanomedicines kill cancer stem cells?
Zhao, Y., Alakhova, D. Y., & Kabanov, A. V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.016 · Cited by 125
“There is an overwhelming body of evidence suggesting that similar to normal tissues, tumors are comprised of heterogeneous cell populations with varying metastatic potential [53–55], angiogenic potential [56] and drug resistance [57, 58].”
BackgroundCaveolin‐1, cancer and therapy resistance
Ketteler, J., & Klein, D. (2018) · International Journal of Cancer · doi:10.1002/ijc.31369 · Cited by 126
“Within its role as a pro-survival protein, overexpression of the multidrug resistance (MDR) transporter P-glycoprotein (P-gp), an ATPase pump that serves as one major cellular detoxifier, was highly correlated with CAV1 in leukemic cells indicating the possibility that the different MDR mechanisms, including regulatio…”
BackgroundFunctions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy
Noguchi, K., Katayama, K., Mitsuhashi, J., & Sugimoto, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.07.003 · Cited by 143
“In a similar fashion to the well-studied multidrug resistant protein P-glycoprotein, which is known to play important roles in the multidrug resistant phenotype of clinical cancer cells [9,10], the overexpression of BCRP renders cancer cells resistant to various chemotherapeutic drugs suchas the topoisomerase I inhibi…”
BackgroundDrug resistance reversal—are we getting closer?
Baird, R. D., & Kaye, S. B. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00619-1 · Cited by 141
Yagüe, E., Armesilla, A. L., Harrison, G., Elliott, J., Sardini, A., Higgins, C. F., & Raguz, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211093200 · Cited by 127
Considerations in the design and development of transport inhibitors as adjuncts to drug therapy
Dantzig, A. H., de Alwis, D. P., & Burgess, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00175-8 · Cited by 152
Molecular imaging of gene expression and protein function in vivo with PET and SPECT
Sharma, V., Luker, G. D., & Piwnica-Worms, D. R. (2002) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.10182 · Cited by 129
“Several other transporters have been shown to transport chemotherapeutic drugs and may be associated with MDR, including the lung resistance protein (LRP) (114); the breast cancer resistance protein (BCRP/MXR/ ABCP), an ABC “half-transporter” (115–117); and MRP2-5 (111).”
BackgroundClassical PKC isoforms in cancer
Martiny‐Baron, G., & Fabbro, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.001 · Cited by 139
“One of the major problems related with anticancer hemotherapy is resistance against anticancer drugs [150,151].”
BackgroundInfluentialTiwari, A. K., Sodani, K., Dai, C.-L., Abuznait, A. H., Singh, S., Xiao, Z.-J., Patel, A., Talele, T. T., Fu, L., Kaddoumi, A., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.10.001 · Cited by 128
“The overexpression of certain ABC transporters such as ABCB1 (Multiple Drug Resistance 1, Pglycoprotein), ABCC/MRP subfamily (Multidrug Resistance Protein) and ABCG2 (Breast Cancer Resistance Protein, MitoXantrone Resistance protein, ATP-Binding Cassette of Placenta) are significantly correlated with MDR in tumor cell…”
BackgroundMilane, L., Ganesh, S., Shah, S., Duan, Z.-F., & Amiji, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.032 · Cited by 128
“Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes.”
BackgroundInfluentialGuo, Y., Zhang, X., Sun, W., Jia, H., Zhu, Y., Zhang, X., Zhou, N., & Wu, F. (2019) · Chemistry of Materials · doi:10.1021/acs.chemmater.9b03042 · Cited by 128
Calcagno, A. M., Fostel, J. M., To, K. K. W., Salcido, C. D., Martin, S. E., Chewning, K. J., Wu, C.-P., Varticovski, L., Bates, S. E., Caplen, N. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604334 · Cited by 126
“Resistance to therapy can result from decreased drug uptake, increased DNA repair or drug inactivation (Gottesman et al, 2002).”
BackgroundSelf-citationWang, H., Lee, D.-K., Chen, K., Chen, J.-Y., Zhang, K., Silva, A., Ho, C., & Ho, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b00638 · Cited by 134
“characterized by system robustness, redundant pathways, crosstalk, anti-target, counter target activity, as well as compensatory and neutralizing actions.(11-16) These complex”
Erdogan, S., Turkekul, K., Dibirdik, I., Doganlar, O., Doganlar, Z. B., Bilir, A., & Oktem, G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.061 · Cited by 123
Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems
Gyanani, V., Haley, J. C., & Goswami, R. (2021) · Pharmaceuticals · doi:10.3390/ph14090835 · Cited by 118
“The development of this drug tolerance is manifested in cancer cells either as modification in a potential drug target or as augmentation of cell survival mechanisms such as DNA repair, changes in apoptotic cycles due to changes in ceramide levels, ineffective tumor suppressor protein (p53) or activation of cytochrome…”
BackgroundColabufo, N. A., Berardi, F., Cantore, M., Contino, M., Inglese, C., Niso, M., & Perrone, R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900743c · Cited by 146
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 134
“Many of the resistance causing mechanisms, especially for non-TKIs, are associated with diminished cellular drug permeability and multidrug resistance efflux transport (Assaraf, 2006; Gottesman et al., 2002).”
BackgroundInvestigational ABC transporter inhibitors
Falasca, M., & Linton, K. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679339 · Cited by 120
“The relevance of ABCB1 in clinical MDR in cancer is unambiguous and other ABC transporters, such as ABCC1 and, less convincingly, ABCG2 have now been implicated [6,68,79].”
BackgroundP‐glycoprotein: So Many Ways to Turn It On
Callaghan, R., Crowley, E., Biochem, M., Potter, S., & Kerr, I. D. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007311568 · Cited by 123
El-Dakdouki, M. H., Zhu, D. C., El-Boubbou, K., Kamat, M., Chen, J., Li, W., & Huang, X. (2012) · Biomacromolecules · doi:10.1021/bm300046h · Cited by 124
Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
Anreddy, N., Gupta, P., Kathawala, R. J., Patel, A. S., Wurpel, J. N. D., & Chen, Z. (2014) · Molecules · doi:10.3390/molecules190913848 · Cited by 131
“ABCB1/P-glycoprotein (P-gp/MDR1) ABCB1 has a molecular weight of 160-170-kDa and consists of two TMDs and two NBDs [28,52].”
BackgroundInfluentialSengupta, S., Mantha, A. K., Mitra, S., & Bhakat, K. K. (2011) · Oncogene · doi:10.1038/onc.2010.435 · Cited by 119
“…occurs due to enhanced expression of MDR1 and other ATP-binding cassette (ABC) transporter proteins in intrinsically drug-resistant cancer cells, as well as in many tumors that acquire drug resistance after chemotherapy (Ambudkar et al., 2005; Gottesman et al., 2002; Gottesman and Pastan, 1993).”
BackgroundInfluentialFrom Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
Valdivia, G., Alonso‐Diez, Á., Alenza, M. D. P., & Peña, L. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.623800 · Cited by 146
“Cancer stem cells are also characterized by the presence of multidrug-resistant (MDR) adenosine triphosphatebinding cassette (ABC) transporter efflux pumps, influencing chemotherapy resistance in cancer due to their capacity to export a wide variety of cell substances (276).”
BackgroundEvolving concepts in cancer therapy through targeting sphingolipid metabolism
Truman, J., García-Barros, M., Obeid, L. M., & Hannun, Y. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.12.013 · Cited by 134
Song, N., Ding, M., Pan, Z., Li, J., Zhou, L., Tan, H. S., & Fu, Q. (2013) · Biomacromolecules · doi:10.1021/bm401342t · Cited by 129
Drug metabolizing enzymes and their inhibitors' role in cancer resistance
Pathania, S., Bhatia, R., Baldi, A., Singh, R., & Rawal, R. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.117 · Cited by 136
ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome
Elliott, A. M., & Al‐Hajj, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0235 · Cited by 127
Gullà, A., Di Martino, M. T., Gallo Cantafio, M. E., Morelli, E., Amodio, N., Botta, C., Pitari, M. R., Lio, S. G., Britti, D., Stamato, M. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0489 · Cited by 120
“determinants ofmultidrug resistance in cancer cells (49).”
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 157
P-glycoprotein and cancer: what do we currently know?
Heming, C. P., Muriithi, W., Macharia, L. W., Filho, P. N., Moura‐Neto, V., & Aran, V. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11171 · Cited by 137
Nanogels: Synthesis, properties, and recent biomedical applications
Duan, Q., Zhu, Y., Jia, H., Wang, S., & Wu, F. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101167 · Cited by 131
Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.002 · Cited by 132
MDR1 expression identifies human melanoma stem cells
Keshet, G. I., Goldstein, I., Itzhaki, O., Cesarkas, K., Shenhav, L., Yakirevitch, A., Treves, A. J., Schachter, J., Amariglio, N., & Rechavi, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.022 · Cited by 124
“Normal stem cells are thought to achieve their longevity by several mechanisms among which are slow divisions, anti apoptotic mechanisms, and expression of efflux pumps that provide protection from toxins [2].”
BackgroundChen, J., Ahn, S., Wang, J., Lü, Y., Dalton, J. T., Miller, D. D., & Li, W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300564b · Cited by 123
Karthikeyan, S., & Hoti, S. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150113103439 · Cited by 111
“This decreased uptake and increased efflux of the drugs are mainly achieved as a function of the membrane bound ATP-binding cassettes (ABC) transporters, a largest protein superfamilies reported in living organisms [6].”
BackgroundEmerging new paradigms for ABCG transporters
Tarr, P. T., Tarling, E. J., Bojanic, D. D., Edwards, P. A., & Baldán, Á. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.01.007 · Cited by 121
“There is substantial evidence for an important role of ABCG2 in determining the efficacy of chemotherapeutic treatments of tumors [80].”
BackgroundStrategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.
Borowski, E., Bontemps‐Gracz, M. M., & Piwkowska, A. (2005) · Acta Biochimica Polonica · doi:10.18388/abp.2005_3421 · Cited by 128
Microtubule Targeting Agents: Basic Mechanisms of Multidrug Resistance (MDR)
Fojo, A. T., & Menefee, M. E. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.010 · Cited by 123
Liao, W., Shen, C., Lin, L., Yang, Y., Han, H.-Y., Chen, J., Kuo, S., Wu, S., & Liaw, C. (2012) · Journal of Natural Products · doi:10.1021/np200866z · Cited by 123
Bera, T. K., Iavarone, C., Vasantha Kumar, M. V., Lee, S. H., Lee, B., & Pastan, I. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102187299 · Cited by 137
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells
Kopecka, J., Campia, I., Jacobs, A., Frei, A. P., Ghigo, D., Wollscheid, B., & Riganti, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2882 · Cited by 117
“As a consequence, tumors overexpressing Pgp often exhibit a MDR phenotype and are difficult to eradicate by chemotherapy [1, 4].”
BackgroundReversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells
Shieh, M., Hsu, C., Huang, L.-Y., Chen, H., Huang, F., & Lai, P. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.017 · Cited by 122
Potential anticancer role of colchicine-based derivatives: an overview
Kumar, A., Sharma, P. R., & Mondhe, D. M. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000464 · Cited by 132
DNA origami/gold nanorod hybrid nanostructures for the circumvention of drug resistance
Song, L., Jiang, Q., Liu, J., Li, N., Liu, Q. L., Dai, L., Gao, Y., Liu, W., Liu, D., & Ding, B. (2017) · Nanoscale · doi:10.1039/c7nr02222k · Cited by 123
RNA interference and potential therapeutic applications of short interfering RNAs
Karagiannis, T. C., & El‐Osta, A. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700857 · Cited by 126
“Although chemosensitizers such as verapamil may be used to circumvent MDR by inhibiting the drug efflux activity of the PGP pump, they are limited by there toxicity at pharmacologically active doses.(102,103) Therefore, RNAi technology offers an alternative method for restoring chemosensitivity in drugresistant cancer…”
BackgroundTurtle, C. J., Delrow, J., Joslyn, R. C., Swanson, H. M., Basom, R., Tabellini, L., Delaney, C., Heimfeld, S., Hansen, J. A., & Riddell, S. R. (2011) · Blood · doi:10.1182/blood-2011-02-334698 · Cited by 120
Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance
Schmidt, F., & Efferth, T. (2016) · Pharmaceuticals · doi:10.3390/ph9020033 · Cited by 121
“Several cellular mechanisms that enhance the occurrence of MDR have been identified, such as (1) increased drug efflux as a result of overexpression of ATP-dependent efflux pumps; (2) activation of detoxifying systems such as cytochrome P450 and glutathione S-transferase; (3) decreased drug uptake; (4) mutated oncogen…”
BackgroundHow to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
Hansen, E., Woods, R. J., & Read, A. F. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001110 · Cited by 132
Liu, J., Ye, Z., Xiang, M., Chang, B., Cui, J., Ji, T., Zhao, L., Li, Q., Deng, Y., Xu, L., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119475 · Cited by 121
Han, N., Zhao, Q., Wan, L., Wang, Y., Gao, Y., Wang, P., Wang, Z., Zhang, J., Jiang, T., & Wang, S. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am5082793 · Cited by 117
Antimicrobial activity of phenothiazines.
Amaral, L., Viveiros, M., & Molnar, J. A. (2004) · PubMed · Cited by 152
Musculin/MyoR is expressed in kidney side population cells and can regulate their function
Hishikawa, K., Marumo, T., Miura, S., Nakanishi, A., Matsuzaki, Y., Shibata, K., Ichiyanagi, T., Kohike, H., Komori, T., Takahashi, I., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200412167 · Cited by 121
“…in protecting the central nervous system through the blood brain barrier (Schinkel et al., 1996), and BCRP1/ABCG2 in the placenta may play a role in protecting fetal blood from toxic organic anions and excreting glutathione/glucuronide metabolites into maternal circulation (Gottesman et al., 2002).”
BackgroundInfluentialEngineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics
Jain, A., Das, M., Swarnakar, N. K., & Jain, S. (2011) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v28.i1.10 · Cited by 129
Taghizadeh, R. R., Noh, M., Huh, Y. H., Ciusani, E., Sigalotti, L., Maio, M., Arosio, B., Nicotra, M. R., Natali, P. G., Sherley, J. L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015183 · Cited by 123
“Among the human ABC superfamily, only ABCB1, ABCC1 (MDR1) and ABCG2 have to date been shown to mediate MDR, each with distinct overlapping efflux substrate specificities and tissue distribution patterns [3].”
BackgroundInfluentialYasuda, H., Nakayama, K., Watanabe, M., Suzuki, S., Fuji, H., Okinaga, S., Kanda, A., Zayasu, K., Sasaki, T., Asada, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1124 · Cited by 116
Ramasamy, T., Ruttala, H. B., Chitrapriya, N., Poudal, B. K., Choi, J. Y., Kim, S. T., Youn, Y. S., Ku, S., Choi, H., Yong, C. S., et al. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.10.034 · Cited by 121
“Doxorubicin (DOX), an anthracycline antibiotic, is one of the most effective anticancer agents used for treatment of a wide variety of solid and hematologic malignancies [5-7].”
BackgroundHow to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Jaramillo, A. C., Saig, F. A., Cloos, J. J., Jansen, G., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.02 · Cited by 124
“kidney, colon, liver, ovarian, breast and sarcomas([4]).”
Xuan, Y., & Hu, X. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.029 · Cited by 123
“resistance, because they either are the substrates/inducers of drug transporters, and/or apoptosis inducers [7–14].”
BackgroundMolecular Mechanism of Chemoresistance by Astrocyte Elevated Gene-1
Yoo, B. K., Chen, D., Su, Z.-Z., Gredler, R., Yoo, J., Shah, K., Fisher, P. B., & Sarkar, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4009 · Cited by 128
Sharma, M., Manoharlal, R., Shukla, S., Puri, N., Prasad, T., Ambudkar, S. V., & Prasad, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01497-08 · Cited by 117
“Among the various strategies to combat MDR, blocking the functioning of MDR transporters represents an attractive approach (11).”
BackgroundA hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics
Xu, X., Sabanayagam, C. R., Harrington, D. A., Farach-Carson, M. C., & Jia, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.080 · Cited by 117
“Drug resistance remains an obstacle to effective chemotherapy of solid tumors [52], and has been attributed to the overexpression of the MDR proteins by tumor cells [12,14].”
BackgroundKe, C., Chiang, W., Liao, Z.-X., Chen, H., Lai, P., Sun, J., & Sung, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.023 · Cited by 121
Shi, Z., Yang, W., Chen, L., Yang, D., Zhou, Q., Zhu, J., Chen, J.-J., Huang, R., Chen, Z., & Huang, R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2196-0 · Cited by 122
“A number of mechanisms that contribute to this phenomenon have been described [1].”
BackgroundMilane, L., Duan, Z., & Amiji, M. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-3 · Cited by 118
“The mechanisms of MDR include decreasing drug influx into a cell, increasing drug efflux out of a cell, increased DNA repair, increased drug metabolism/ detoxification, and decreased apoptosis [7].”
BackgroundInfluentialGraphene oxide used as a carrier for adriamycin can reverse drug resistance in breast cancer cells
Wu, J., Wang, Y., Yang, X., Liu, Y.-Y., Yang, J., Yang, R., & Zhang, N. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/35/355101 · Cited by 121
Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
Harris, K. S., & Kerr, B. A. (2017) · Stem Cells International · doi:10.1155/2017/8629234 · Cited by 125
“ABCG2 Recurrence and therapeutic resistance [49, 73, 75]”
Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment
Qu, Y., Dou, B., Tan, H., Feng, Y., Wang, N., & Wang, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0992-4 · Cited by 126
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
Pan, Y., Deng, C., Qiu, Z., Cao, C., & Wu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713530 · Cited by 130
Brooks, T. A., Minderman, H., O’Loughlin, K. L., Pera, P. J., Ojima, I., Baer, M. R., Bernacki, R. J., & Brooks, T. A. (2003) · PubMed · Cited by 134
Functional interaction of intestinal CYP3A4 and P‐glycoprotein
Kivistö, K. T., Niemi, M., & Fromm, M. F. (2004) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00291.x · Cited by 120
Regulation of the Stability of P-Glycoprotein by Ubiquitination
Zhang, Z., Wu, J., Hait, W. N., & Yang, J. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001966 · Cited by 119
“multidrug resistance-associated protein, breast cancer resistance protein, and lung cancer resistance protein are ubiquitinated, because these ABC transporters share many similarities (Gottesman et al., 2002).”
BackgroundA Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
Abraham, J., Edgerly, M., Wilson, R. H., Chen, C. C., Rutt, A., Bakke, S., Robey, R. W., Dwyer, A., Goldspiel, B. R., Balis, F. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0938 · Cited by 119
“Nonhematologic grade 3/4 toxicities in 77 cycles included the following: abdominal pain (4 cycles), anorexia (2), constipation (2), fatigue (3), myalgia (2), pain (4) and dehydration, depression, diarrhea, ileus, nausea, and vomiting, (all once).”
Self-citationGurunathan, S., & Zhang, X. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s111279 · Cited by 119
“The successful treatment of cancer is a tedious process due to multidrug resistance (MDR) and/or apoptosis resistance to chemotherapy, which are frequently obtained by various mechanisms.(5) Recent studies suggest that a small subset of distinct cells termed cancer stem cells (CSCs) are responsible for tumor initiatio…”
Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells
Chartrain, M., Riond, J., Stennevin, A., Vandenberghe, I., Gomes, B., Lamant, L., Meyer, N., Gairin, J. E., Guilbaud, N., & Annereau, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036762 · Cited by 118
“transporters which have been associated with multidrug resistance by lowering the intracellular accumulation of cytotoxic drugs [9].”
Regulations of P-Glycoprotein/ABCB1/MDR1in Human Cancer Cells
Katayama, K., Noguchi, K., & Sugimoto, Y. (2014) · New Journal of Science · doi:10.1155/2014/476974 · Cited by 118
Huang, I.-P., Sun, S.-P., Cheng, S.-H., Lee, C.-H., Wu, C.-Y., Yang, C.-S., Lo, L.-W., & Lai, Y.-K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0884 · Cited by 118
“Mol Cancer Ther; 10(5) May 2011 Molecular Cancer Therapeutics 762”
BackgroundInfluentialNicklisch, S. C. T., Rees, S. D., McGrath, A. P., Gökirmak, T., Bonito, L. T., Vermeer, L. M. M., Cregger, C., Loewen, G. J., Sandin, S. A., Chang, G. A., et al. (2016) · Science Advances · doi:10.1126/sciadv.1600001 · Cited by 118
Zhou, Y. M., Wang, Y., Zhou, W., Chen, T., Wu, Q., Chutturghoon, V. K., Lin, B., Geng, L., Yang, Z., Zhou, L., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0898-7 · Cited by 129
Highlights in Resistance Mechanism Pathways for Combination Therapy
Delou, J. M. D. A., Souza, A. S. O., Souza, L. C. D. M. E., & Borges, H. L. (2019) · Cells · doi:10.3390/cells8091013 · Cited by 128
“ABC transporters can bind anticancer drugs either from the surroundings of the plasma membrane or intracellular vesicles, and transport them out of the cell directly to the external milieu or through exocytosis [18].”
Small molecule photocatalysis enables drug target identification via energy transfer
Trowbridge, A., Seath, C. P., Rodriguez‐Rivera, F. P., Li, B. X., Dul, B. E., Schwaid, A. G., Buksh, B. F., Geri, J. B., Oakley, J. V., Fadeyi, O., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208077119 · Cited by 126
Modulation of Cellular Cholesterol Alters P-Glycoprotein Activity in Multidrug-Resistant Cells
Troost, J., Lindenmaier, H., Haefeli, W. E., & Weiß, J. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.002329 · Cited by 118
“In case of overexpression, P-glycoprotein may confer multidrug resistance (MDR), leading to failure of drug therapies for cancer (Gottesman et al., 2002) and AIDS (Lee et al.”
Zhong, Y., Wang, C., Cheng, L., Meng, F., Zhong, Z., & Liu, Z. (2013) · Biomacromolecules · doi:10.1021/bm400530d · Cited by 119
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors
Dalvi, M. P., Wang, L., Zhong, R., Kollipara, R. K., Park, H., Bayo, J., Yenerall, P. M., Zhou, Y., Timmons, B. C., Rodriguez‐Canales, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.077 · Cited by 123
“The most commonly implicated mechanism for acquisition of resistance to taxanes involves increased expression of drug efflux transporters such as MDR1, resulting in cross-resistance to other chemotherapies (Gottesman et al., 2002).”
BackgroundEmerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
Cornelison, R., Llaneza, D. C., & Landen, C. N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102171 · Cited by 130
“Drug efflux pumps (adenosine triphosphate (ATP) binding cassette (ABC) transporters) lower drug concentrations within cells (reviewed in [24] with follow-up [25]), and therapeutic agents can be biochemically degraded through detoxifying enzymes such as cytochrome p450 and glutathione transferases (reviewed in [26,27]).”
BackgroundMicroRNAs as novel biomarkers for colorectal cancer: New outlooks
Shirafkan, N., Mansoori, B., Mohammadi, A., Shomali, N., Ghasbi, M., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.046 · Cited by 124
Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-30158-6 · Cited by 114
Yan, T., He, J., Liu, R., Liu, Z., & Cheng, J. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115706 · Cited by 118
Mechanisms of chemotherapy resistance in ovarian cancer
Ortiz, M. M. O., Wabel, E., Mitchell, K., & Horibata, S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.147 · Cited by 157
Martins-Neves, S. R., Lopes, Á. O., do Carmo, A., Paiva, A. A., Simões, P. C., Abrunhosa, A. J., & Gomes, C. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-139 · Cited by 111
“These transmembrane proteins behave as drug efflux pumps of most chemotherapeutic agents preventing their intracellular accumulation at toxic concentrations [13].”
SYNTHESIS: Cancer research meets evolutionary biology
Pepper, J. W., Scott Findlay, C., Kassen, R., Spencer, S. L., & Maley, C. C. (2009) · Evolutionary Applications · doi:10.1111/j.1752-4571.2008.00063.x · Cited by 109
“The reasons for this failure are unknown, but may be due to single mutations that upregulate efflux pumps causing multidrug resistance [52].”
BackgroundSoranzo, N., Gl, C., Weale, M. E., Wood, N. W., Depondt, C., Marguerie, R., Sisodiya, S. M., & Goldstein, D. B. (2004) · Genome Research · doi:10.1101/gr.1965304 · Cited by 129
“…drugs (immunosuppressants, Lown et al. 1997; cardiac glycosides, de Lannoy and Silverman 1992; Ito et al. 1992; HIV-1 protease inhibitors, Kim et al. 1998; Polli et al. 1999; -blockers, SpahnLangguth et al. 1998; and many others, Bellamy 1996; Fromm 2002; Gottesman et al. 2002; Wandel et al. 2002).”
Gelsomino, G., Corsetto, P. A., Campia, I., Montorfano, G., Kopecka, J., Castella, B., Gazzano, E., Ghigo, D., Rizzo, A. M., & Riganti, C. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-137 · Cited by 123
“According to its structure, BCRP is less hydrophobic than Pgp and MRP1 [27].”
BackgroundInfluential
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.